Humacyte, Inc.
HealthcareNASDAQ:HUMA · NASDAQ Global Select
-$0.03 today
Vol 9.06M · Avg 7.58M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-1313.4%
avg -291.4%
ROIC
-107.0%
avg -68.8%
ROA
-35.1%
avg -51.1%
Analysis
ROA is currently the strongest return metric at -35.1% versus its period average of -51.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Laura E. Niklason | Founder, President, Chief Executive Officer & Director | $902,183.00 | — | 63 | $80,000.00 | 0.05% |
Dale A. Sander | Chief Financial Officer, Chief Corporate Development Officer & Treasurer | $735,503.00 | — | 66 | $267,213.00 | 0.16% |
Shamik J. Parikh | Chief Medical Officer | $700,401.00 | — | 53 | $272,713.00 | 0.16% |
Jim Mercadante | Chief Commercial Officer | — | — | — | — | — |
Heather Connelly | Executive Vice President Regulatory Affairs & Quality | — | — | — | $283,101.00 | 0.17% |
Rick McElheny | Senior Vice President of Business Development | — | — | — | — | — |
Lisa Molyneux | Executive Vice President of Enterprise Planning & Analysis | — | — | — | — | — |
Todd E. Rasmussen | Chief Surgical Officer | — | — | — | $80,000.00 | 0.05% |
Sabrina Osborne | Chief People Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$59,839.34
Sells
8
$7.55M
Net Sentiment
$7.49M
Net selling
Most Active
Niklason Laura E
3 transactions
Analysis
Insiders reported 2 buys worth $59,839.34 and 8 sells worth $7.55M over the last 12 months. That adds up to net selling of $7.49M. Niklason Laura E was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$566.68M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$353.00M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$250.78M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Who manages HUMA?
Humacyte, Inc. (HUMA) lists 9 active executives. The top listed executive is Laura E. Niklason, Founder, President, Chief Executive Officer & Director.
Are HUMA insiders buying or selling?
Recent insider activity shows net selling of $124.60M.
Explore More
Continue the stock analysis
Jump to another research area for this company.